187 related articles for article (PubMed ID: 37858275)
1. Pharmacological EZH2 inhibition combined with retinoic acid treatment promotes differentiation and apoptosis in rhabdomyosarcoma cells.
O'Brien E; Tse C; Tracy I; Reddin I; Selfe J; Gibson J; Tapper W; Pengelly RJ; Gao J; Aladowicz E; Petts G; Thway K; Popov S; Kelsey A; Underwood TJ; Shipley J; Walters ZS
Clin Epigenetics; 2023 Oct; 15(1):167. PubMed ID: 37858275
[TBL] [Abstract][Full Text] [Related]
2. The Polycomb group (PcG) protein EZH2 supports the survival of PAX3-FOXO1 alveolar rhabdomyosarcoma by repressing FBXO32 (Atrogin1/MAFbx).
Ciarapica R; De Salvo M; Carcarino E; Bracaglia G; Adesso L; Leoncini PP; Dall'Agnese A; Walters ZS; Verginelli F; De Sio L; Boldrini R; Inserra A; Bisogno G; Rosolen A; Alaggio R; Ferrari A; Collini P; Locatelli M; Stifani S; Screpanti I; Rutella S; Yu Q; Marquez VE; Shipley J; Valente S; Mai A; Miele L; Puri PL; Locatelli F; Palacios D; Rota R
Oncogene; 2014 Aug; 33(32):4173-84. PubMed ID: 24213577
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological inhibition of EZH2 as a promising differentiation therapy in embryonal RMS.
Ciarapica R; Carcarino E; Adesso L; De Salvo M; Bracaglia G; Leoncini PP; Dall'agnese A; Verginelli F; Milano GM; Boldrini R; Inserra A; Stifani S; Screpanti I; Marquez VE; Valente S; Mai A; Puri PL; Locatelli F; Palacios D; Rota R
BMC Cancer; 2014 Feb; 14():139. PubMed ID: 24575771
[TBL] [Abstract][Full Text] [Related]
4. JARID2 is a direct target of the PAX3-FOXO1 fusion protein and inhibits myogenic differentiation of rhabdomyosarcoma cells.
Walters ZS; Villarejo-Balcells B; Olmos D; Buist TW; Missiaglia E; Allen R; Al-Lazikani B; Garrett MD; Blagg J; Shipley J
Oncogene; 2014 Feb; 33(9):1148-57. PubMed ID: 23435416
[TBL] [Abstract][Full Text] [Related]
5. 12-O-tetradecanoylphorbol-13-acetate and EZH2 inhibition: A novel approach for promoting myogenic differentiation in embryonal rhabdomyosarcoma cells.
Marchesi I; Sanna L; Fais M; Fiorentino FP; Giordano A; Bagella L
J Cell Physiol; 2018 Mar; 233(3):2360-2365. PubMed ID: 28722764
[TBL] [Abstract][Full Text] [Related]
6. Differentiation of rhabdomyosarcoma cell lines using retinoic acid.
Barlow JW; Wiley JC; Mous M; Narendran A; Gee MF; Goldberg M; Sexsmith E; Malkin D
Pediatr Blood Cancer; 2006 Nov; 47(6):773-84. PubMed ID: 16283617
[TBL] [Abstract][Full Text] [Related]
7. Response of human rhabdomyosarcoma cell lines to retinoic acid: relationship with induction of differentiation and retinoic acid sensitivity.
Ricaud S; Vernus B; Bonnieu A
Exp Cell Res; 2005 Dec; 311(2):192-204. PubMed ID: 16236281
[TBL] [Abstract][Full Text] [Related]
8. Dissecting the role of novel EZH2 inhibitors in primary glioblastoma cell cultures: effects on proliferation, epithelial-mesenchymal transition, migration, and on the pro-inflammatory phenotype.
Stazi G; Taglieri L; Nicolai A; Romanelli A; Fioravanti R; Morrone S; Sabatino M; Ragno R; Taurone S; Nebbioso M; Carletti R; Artico M; Valente S; Scarpa S; Mai A
Clin Epigenetics; 2019 Dec; 11(1):173. PubMed ID: 31791385
[TBL] [Abstract][Full Text] [Related]
9. Enhancer of zeste homologue 2 plays an important role in neuroblastoma cell survival independent of its histone methyltransferase activity.
Bate-Eya LT; Gierman HJ; Ebus ME; Koster J; Caron HN; Versteeg R; Dolman MEM; Molenaar JJ
Eur J Cancer; 2017 Apr; 75():63-72. PubMed ID: 28214660
[TBL] [Abstract][Full Text] [Related]
10. Targeting EZH2-mediated methylation of histone 3 inhibits proliferation of pediatric acute monocytic leukemia cells
Al-Ghabkari A; Narendran A
Cancer Biol Ther; 2021 Apr; 22(4):333-344. PubMed ID: 33978549
[TBL] [Abstract][Full Text] [Related]
11. The ablation of EZH2 uncovers its crucial role in rhabdomyosarcoma formation.
Marchesi I; Fiorentino FP; Rizzolio F; Giordano A; Bagella L
Cell Cycle; 2012 Oct; 11(20):3828-36. PubMed ID: 22983009
[TBL] [Abstract][Full Text] [Related]
12. Combined Inhibition of G9a and EZH2 Suppresses Tumor Growth via Synergistic Induction of IL24-Mediated Apoptosis.
Casciello F; Kelly GM; Ramarao-Milne P; Kamal N; Stewart TA; Mukhopadhyay P; Kazakoff SH; Miranda M; Kim D; Davis FM; Hayward NK; Vertino PM; Waddell N; Gannon F; Lee JS
Cancer Res; 2022 Apr; 82(7):1208-1221. PubMed ID: 35149587
[TBL] [Abstract][Full Text] [Related]
13. Arsenic trioxide induces the differentiation of retinoic acid-resistant neuroblastoma cells via upregulation of HoxC9.
Li C; Feng C; Chen Y; Wu P; Li P; Xiong X; Peng X; Wang Z; Li Y
Adv Clin Exp Med; 2022 Aug; 31(8):903-911. PubMed ID: 35467087
[TBL] [Abstract][Full Text] [Related]
14. Retinoic acid fails to induce cell cycle arrest with myogenic differentiation in rhabdomyosarcoma.
Al-Tahan A; Sarkis O; Harajly M; Baghdadi OK; Zibara K; Boulos F; Dighe D; Kregel S; Bazarbachi A; El-Sabban M; Skapek SX; Saab R
Pediatr Blood Cancer; 2012 Jun; 58(6):877-84. PubMed ID: 21755593
[TBL] [Abstract][Full Text] [Related]
15. The histone deacetylase inhibitor Suberoylanilide Hydroxamic Acid (SAHA) as a therapeutic agent in rhabdomyosarcoma.
Ghayad SE; Rammal G; Sarkis O; Basma H; Ghamloush F; Fahs A; Karam M; Harajli M; Rabeh W; Mouawad JE; Zalzali H; Saab R
Cancer Biol Ther; 2019; 20(3):272-283. PubMed ID: 30307360
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of PRC2 histone methyltransferase activity increases TRAIL-mediated apoptosis sensitivity in human colon cancer cells.
Benoit YD; Laursen KB; Witherspoon MS; Lipkin SM; Gudas LJ
J Cell Physiol; 2013 Apr; 228(4):764-72. PubMed ID: 23001792
[TBL] [Abstract][Full Text] [Related]
17. The Effect of Direct and Indirect EZH2 Inhibition in Rhabdomyosarcoma Cell Lines.
Schmidt A; Behrendt L; Eybe J; Warmann SW; Schleicher S; Fuchs J; Schmid E
Cancers (Basel); 2021 Dec; 14(1):. PubMed ID: 35008205
[TBL] [Abstract][Full Text] [Related]
18. Histone H3K27 methyltransferase EZH2 and demethylase JMJD3 regulate hepatic stellate cells activation and liver fibrosis.
Jiang Y; Xiang C; Zhong F; Zhang Y; Wang L; Zhao Y; Wang J; Ding C; Jin L; He F; Wang H
Theranostics; 2021; 11(1):361-378. PubMed ID: 33391480
[No Abstract] [Full Text] [Related]
19. The synthetic retinoid ST1926 as a novel therapeutic agent in rhabdomyosarcoma.
Basma H; Ghayad SE; Rammal G; Mancinelli A; Harajly M; Ghamloush F; Dweik L; El-Eit R; Zalzali H; Rabeh W; Pisano C; Darwiche N; Saab R
Int J Cancer; 2016 Mar; 138(6):1528-37. PubMed ID: 26453552
[TBL] [Abstract][Full Text] [Related]
20. PAX3-FOXO1 drives miR-486-5p and represses miR-221 contributing to pathogenesis of alveolar rhabdomyosarcoma.
Hanna JA; Garcia MR; Lardennois A; Leavey PJ; Maglic D; Fagnan A; Go JC; Roach J; Wang YD; Finkelstein D; Hatley ME
Oncogene; 2018 Apr; 37(15):1991-2007. PubMed ID: 29367756
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]